Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized study of radiotherapy plus nituzumab with capecitabine maintenance versus concurrent carboplatin chemoradiotherapy in elderly locally advanced nasopharyngeal carcinoma after induction chemotherapy
ChiCTR2400085594Phase 2Recruiting
- Sponsor
- Dongguan People's Hospital
- Start
- Jun 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nimotuzumab, capecitabine and carboplatin in nasopharyngeal carcinoma (NPC) (3 arms), sponsored by Dongguan People's Hospital. Primary endpoint: Two-year disease-free survival rate. Started Jun 2024; status: recruiting.
02
Drugs
nimotuzumabcapecitabinecarboplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2400085594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085594.